Community Academic Profiles–

Paul Heidenreich, MD

Back to Profile

Publication Details

  • Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction.

    Hernandez AF, Mi X, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Qualls LG, Peterson ED, Fonarow GC, Curtis LH. JAMA. 2012; 308 (20): 2097-107

    Aldosterone antagonist therapy for heart failure and reduced ejection fraction has been highly efficacious in randomized trials. However, questions remain regarding the effectiveness and safety of the therapy in clinical practice.

    PubMedID: 23188026

Stanford Medicine Resources:

Footer Links: